Heart Sounds Registry

NCT ID: NCT03203629

Last Updated: 2021-04-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

705 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-06-05

Study Completion Date

2021-03-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To conduct a prospective, observational study to evaluate the non-interventional feasibility of using heart sounds measurements recorded by the LifeVest® Wearable Cardioverter Defibrillator (WCD) for monitoring clinical evidence of heart failure decompensation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To conduct a prospective, observational study to evaluate the non-interventional feasibility of using heart sounds measurements recorded by the LifeVest® Wearable Cardioverter Defibrillator (WCD) for monitoring clinical evidence of heart failure decompensation.

Participants will be adult (age ≥ 18 years) heart failure patients with an ejection fraction (EF) ≤ 35% and eligible to wear the WCD for at least 3 months.

An FDA-approved WCD will be prescribed for at least 3 months of use after hospital discharge.

This is a multi-center, prospective, observational study.

The study will enroll a total of 300 subjects, anticipating that at least 250 subjects will complete the study. A maximum of 50 sites will enroll patients into the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure; With Decompensation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Wearable Cardioverter Defibrillator (WCD)

Observe and compare the heart sound measurements recorded by the WCD

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LifeVest WCD

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who are prescribed the WCD ≤ 10 days post-discharge after hospitalization with Heart Failure (HF), with and ischemic or non-ischemic cardiomyopathy.
* Patients who have an ejection fraction (EF) ≤ 35% at the time of WCD prescription.
* Patients are anticipated to wear the WCD for at least 3 months.
* The subject must be 18 years of age or older on the day of screening.

Exclusion Criteria

* Patients with pacemakers, an implanted cardioverter defibrillator (ICD), or a cardiac resynchronization therapy device.
* Patients waiting for heart transplant.
* Patients with known evidence of atrial fibrillation on their most recent ECG recording.
* Patients currently hospitalized for acute myocardial infarction.
* Patients with a planned revascularization within 30 days of screening.
* Patients who are self-reporting to be pregnant.
* Patients participating in another clinical study.
* Patients not expected to live longer than 1 year.
* For patients in the United States, those who are unable or unwilling to provide written informed consent in English.
* For patients in Europe, those who are unable or unwilling to provide written informed consent in their country specific language or English.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zoll Medical Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Steven J. Szymkiewicz, MD

Role: STUDY_DIRECTOR

Zoll Medical Corporation

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MD Strategies Research Center

National City, California, United States

Site Status

JFK Medical Center

Atlantis, Florida, United States

Site Status

Holy Cross Hospital

Fort Lauderdale, Florida, United States

Site Status

Northside Hospital / Heart Institute

St. Petersburg, Florida, United States

Site Status

Carle Foundation Hospital

Urbana, Illinois, United States

Site Status

FRANCISCAN HEALTH Indianapolis

Indianapolis, Indiana, United States

Site Status

Cardiovascular Institute of Michigan

Clinton Township, Michigan, United States

Site Status

Genesys Regional Medical Center

Grand Blanc, Michigan, United States

Site Status

Sparrow Clinical Research Institute

Lansing, Michigan, United States

Site Status

Michigan CardioVascular Institute

Saginaw, Michigan, United States

Site Status

Virtua The Cardiology Group

Moorestown, New Jersey, United States

Site Status

Virtua The Cardiology Group

Voorhees Township, New Jersey, United States

Site Status

Saratoga Clinical Research

Saratoga Springs, New York, United States

Site Status

MD First Research

Anderson, South Carolina, United States

Site Status

McLeod Regional

Florence, South Carolina, United States

Site Status

Chippenham Medical Center

Richmond, Virginia, United States

Site Status

West Virginia University Research

Morgantown, West Virginia, United States

Site Status

Medizinische Universität Graz

Graz, , Austria

Site Status

Charité Berlin Benjamin Franklin

Berlin, , Germany

Site Status

Herzzentrum Dresden

Dresden, , Germany

Site Status

Uni Erlangen

Erlangen, , Germany

Site Status

Universitätsklinikum Frankfurt

Frankfurt, , Germany

Site Status

Albertinenkrankenhaus HamburgKardiologie Albertinen-Krankenhaus

Hamburg, , Germany

Site Status

Asklepios St. Georg Hamburg

Hamburg, , Germany

Site Status

Sana Klinikum Hof,

Hof, , Germany

Site Status

Krankenhaus und MVZ Maria-Hilf Stadtlohn GmbH

Stadtlohn, , Germany

Site Status

University of Würzburg, Medizinische Klinik und Poliklinik I

Würzburg, , Germany

Site Status

American Heart of Poland S.A.

Chrzanów, , Poland

Site Status

Wissmed Gdanskie Centrum

Gdansk, , Poland

Site Status

Klinika Elektrokardiologii Uniwersytetu Medycznego w Lodzi

Lodz, , Poland

Site Status

Spzoz Msw

Rzeszów, , Poland

Site Status

EMED Centrum Uslug Medycznych

Rzeszów, , Poland

Site Status

Wojewodzki Szpital Zespolony

Torun, , Poland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Austria Germany Poland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

90D0164

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The HF-HRV Registry
NCT00236236 COMPLETED
INSIGHTS ICD Registry
NCT00279968 COMPLETED
SMARTHEART Validation Study
NCT04755582 UNKNOWN